13 — HUTCHMED (China) Share News
0.000.00%
Last trade - 00:00- HK$23.71bn
- HK$17.94bn
- $630.20m
RCS - Hutchmed China Ltd - HUTCHMED and Innovent Announce NDA Acceptance
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights SACHI Phase III Data at ASCO
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Data to be Presented at ASCO
AnnouncementREG - Hutchmed China Ltd - AGM held on May 13, 2025 – Poll Results
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED - Data to be Presented at AACR 2025
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Completes Enrollment of Phase II Study
AnnouncementREG - Hutchmed China Ltd - 2024 Annual Report and Notice of AGM
AnnouncementREG - Hutchmed China Ltd - Extraordinary General Meeting – Poll Results
AnnouncementRCS - Hutchmed China Ltd - NMPA Conditional Approval for TAZVERIK®
AnnouncementREG - Hutchmed China Ltd - Retirement of Independent Non-executive Directors
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Savolitinib SAVANNAH Phase II
AnnouncementRCS - Hutchmed China Ltd - Publication of Form 20-F
AnnouncementREG - Hutchmed China Ltd - 2024 Final Results and Business Updates
AnnouncementRCS - Hutchmed China Ltd - Phase II/III Study of Fruquintinib and Sintilimab
AnnouncementREG - Hutchmed China Ltd - Adoption of the 2025 Long Term Incentive Plan
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under Long Term Incentive Plan
AnnouncementREG - Hutchmed China Ltd - Notice of Extraordinary General Meeting
AnnouncementRCS - Hutchmed China Ltd - Completed Enrollment of Phase II Study
Announcement